⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Novavax sells Czech manufacturing facility to Novo Nordisk for $200 mln

Published 04/12/2024, 09:08 pm
© Reuters
NVAX
-
NVO
-

Investing.com -- Novavax (NASDAQ:NVAX), a biotechnology company known for its protein-based vaccines, has entered into an agreement to sell its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk (CSE:NOVOb) for $200 million. 

The deal is part of Novavax’s broader strategy to streamline its operations and focus on its core pipeline and technology platform.

The transaction includes the transfer of a 150,000-square-foot, state-of-the-art facility specializing in recombinant protein manufacturing, along with related infrastructure and the existing workforce. 

As part of the agreement, Novo Nordisk will pay $190 million upfront in 2024, with an additional $10 million due in 2025.

Novavax has described the sale as a key move in its efforts to become a leaner and more agile organization. 

The company said that the transaction would not only provide a significant cash infusion but also result in annual operating cost savings of approximately $80 million.

“We are grateful to our colleagues in the Czech Republic for their contributions and look forward to collaborating with Novo Nordisk to ensure a seamless transition,” said John C. Jacobs, Novavax’s President and CEO in a statement.

Novo Nordisk will assume full responsibility for the facility upon the deal’s expected closure by December 30, 2024.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.